Targeted Ultrasound With Contrast Enhancement for Reassessment of MRI‐Detected BI‐RADS 4 Nonmass Enhancement: Impact on Biopsy Reduction and DCIS Detection
The Breast Journal · 2026-01 · 2026 (1)
DOI: 10.1155/tbj/1932231 ↗Abstract
Objective To evaluate whether targeted ultrasound (TUS) combined with contrast‐enhanced ultrasound (CEUS) can safely reclassify MRI‐detected BI‐RADS 4 nonmass enhancement (NME) lesions to reduce unnecessary biopsies while maintaining high diagnostic sensitivity for breast cancer. Materials and Methods In this prospective study (2017–2023), we enrolled 169 MRI‐detected BI‐RADS 4 NME lesions in 167 women (23–84 years). All patients underwent TUS and CEUS within one week after MRI, followed by surgical pathology. We evaluated whether TUS combined with CEUS could reclassify lesions to avoid biopsy without compromising cancer detection. Results Among 169 lesions (83 benign, 86 malignant), TUS detected 97.0%. Using predefined CEUS benign criteria, 36/83 benign lesions (43.4%) and 39/169 overall (23.1%) could have safely avoided biopsy. Diagnostic sensitivity remained high (96.5%, 83/86). CEUS significantly improved detection of DCIS, upgrading 87.5% (21/24) of MRI‐BI‐RADS 4a DCIS/DCIS with microinvasion to BI‐RADS ≥4b. False‐negative cases were limited to three lesions in challenging anatomical locations (subareolar or occult). Biopsy reduction was highest in asymptomatic patients, lesions ≤ 2 cm, homogeneous enhancement, and MRI BI‐RADS 4a. Conclusions TUS combined with CEUS can substantially reduce unnecessary biopsies for MRI‐detected BI‐RADS 4 NME while maintaining excellent sensitivity. This approach is particularly effective for MRI BI‐RADS 4a lesions and small homogeneous NME and may provide a clinically practical strategy for improving diagnostic efficiency in breast cancer care.
EUVIMED